The addition of immune checkpoint inhibitors to the renal cell carcinoma armamentarium has significantly changed the treatment of this disease. In 2021, Keytruda (Merck & Co.) became the first immune checkpoint inhibitor to gain approval as an adjuvant treatment for early-stage renal cell carcinoma. In the metastatic setting, combination therapies incorporating immune checkpoint inhibitors (with or without tyrosine kinase inhibitors) have revolutionized the treatment cascade. The approvals of Opdivo (Bristol-Myers Squibb / Ono Pharmaceutical) plus Cabometyx (Exelixis) and Keytruda plus Lenvima / Kisplyx (Eisai) in 2021 provide alternative options for patients and competition for Opdivo plus Yervoy (Bristol-Myers Squibb / Ono Pharmaceutical) and Keytruda plus Inlyta (Pfizer). As uptake of these novel regimens increases, successful drug differentiation strategies will be crucial to ensure physician uptake and preference in this rapidly changing environment.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States.
Primary research: Survey of 101 U.S. medical oncologists.
Key drugs covered: Keytruda, Opdivo, Yervoy, Imfinzi, Cabometyx, Inlyta, Lenvima, Fotivda, Welireg.